Lce1i inhibitors represent a distinct category of chemical compounds intricately designed to interact with the Lce1i protein. This protein is a member of the Late Cornified Envelope (Lce) protein family, which plays a pivotal role in skin biology, particularly in the development of the cornified envelope of the skin's outermost layer. The Lce1i protein, like its family counterparts, is noted for its unique expression patterns, primarily in the epidermal layers of the skin. The specificity of Lce1i inhibitors is a testament to the sophisticated molecular engineering involved in their development, aimed at achieving a targeted and effective interaction with the Lce1i protein. The process of developing these inhibitors is rooted in a comprehensive understanding of the molecular structure and function of the Lce1i protein, a focus that is crucial for the creation of effective inhibitory compounds.
The journey to develop Lce1i inhibitors encompasses advanced techniques in medicinal chemistry and molecular biology. Researchers delve into the intricate molecular structure of the Lce1i protein to design inhibitors that are both specific and effective. The interaction between these inhibitors and the Lce1i protein is central to their efficacy, with a particular emphasis on the formation of a complex where the inhibitor binds to specific sites on the protein. This interaction necessitates a precise alignment of molecular structures, often involving the creation of hydrogen bonds and other molecular interactions. In designing Lce1i inhibitors, various factors such as the compound's stability, solubility, and the ability to reach the intended target within biological systems are taken into account. This includes balancing the hydrophobic and hydrophilic properties of the compound and considering its molecular size and shape. The sophisticated process of designing Lce1i inhibitors underscores the complexity and specificity required in targeting specific proteins, highlighting the advanced state of current research techniques in the fields of biochemistry and pharmacology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
A cytidine analog that incorporates into DNA and RNA and inhibits DNA methyltransferases, potentially causing DNA demethylation and disturbance of gene expression. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
Similar to 5-azacytidine, it is a DNA methyltransferase inhibitor that may lead to gene reactivation and altered gene expression patterns. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $131.00 $515.00 | 2 | |
A non-nucleoside DNA methyltransferase inhibitor which may prevent DNA methylation, potentially affecting gene transcription. | ||||||
Hydralazine-15N4 Hydrochloride | 304-20-1 (unlabeled) | sc-490605 | 1 mg | $480.00 | ||
Traditionally used as an antihypertensive agent, it can inhibit DNA methylation and modify gene expression. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
It binds to GC-rich sequences in the DNA, blocking transcription factors and potentially downregulating gene expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Sirolimus binds to mTOR and can downregulate protein synthesis, affecting the expression of many genes. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Another analog of sirolimus and inhibitor of mTOR, potentially affecting the expression of certain genes. | ||||||
BEZ235 | 915019-65-7 | sc-364429 | 50 mg | $211.00 | 8 | |
A dual inhibitor of PI3K and mTOR, which could result in the inhibition of the PI3K/AKT/mTOR pathway, affecting gene expression. | ||||||